BriaCell Therapeutics Corp. (BCTX) stock
BCTXNasdaqPharmaceutical PreparationsFiscal year ends July 31Also trades as BCTXL, BCTXZ
$3.51−0.08 (-2.23%)
Close on Nov 12, 2026Market cap $30.65MP/E –Yield –
BriaCell Therapeutics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BriaCell Therapeutics's ebitda for the twelve months ending Apr 30, 2023 was -$20.79M. For fiscal 2022 it was -$15.27M.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2022 | Jul 31, 2022 | -$15.27M | – |
| FY2021 | Jul 31, 2021 | -$6.96M | – |
| FY2020 | Jul 31, 2020 | -$3.92M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2025CQ1 2025 | Apr 30, 2025 | -$6.30M | – |
| Q3 FY2024CQ1 2024 | Apr 30, 2024 | -$9.23M | – |
| Q2 FY2024CQ4 2023 | Jan 31, 2024 | -$9.83M | – |
| Q1 FY2024CQ3 2023 | Oct 31, 2023 | -$8.50M | – |
| Q3 FY2023CQ1 2023 | Apr 30, 2023 | -$5.67M | – |
| Q2 FY2023CQ4 2022 | Jan 31, 2023 | -$4.48M | – |
| Q1 FY2023CQ3 2022 | Oct 31, 2022 | -$5.40M | – |
| Q4 FY2022CQ2 2022 | Jul 31, 2022 | -$5.23M | – |
| Q3 FY2022CQ1 2022 | Apr 30, 2022 | -$4.12M | – |
| Q2 FY2022CQ4 2021 | Jan 31, 2022 | -$3.64M | – |
| Q1 FY2022CQ3 2021 | Oct 31, 2021 | -$2.28M | – |
| Q4 FY2021CQ2 2021 | Jul 31, 2021 | -$1.60M | – |
| Q3 FY2021CQ1 2021 | Apr 30, 2021 | -$4.80M | – |
See a number that looks wrong?